[go: up one dir, main page]

DK1885187T3 - Fremgangsmåde til behandling af lægemiddelresistent cancer - Google Patents

Fremgangsmåde til behandling af lægemiddelresistent cancer

Info

Publication number
DK1885187T3
DK1885187T3 DK06752445.4T DK06752445T DK1885187T3 DK 1885187 T3 DK1885187 T3 DK 1885187T3 DK 06752445 T DK06752445 T DK 06752445T DK 1885187 T3 DK1885187 T3 DK 1885187T3
Authority
DK
Denmark
Prior art keywords
compound
resistant cancer
treating drug
tautomer
salt
Prior art date
Application number
DK06752445.4T
Other languages
English (en)
Inventor
Glenn C Michelson
Vivien W Chan
Carla C Heise
Marion Wiesmann
Timothy D Dawes
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1885187T3 publication Critical patent/DK1885187T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK06752445.4T 2005-05-13 2006-05-10 Fremgangsmåde til behandling af lægemiddelresistent cancer DK1885187T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68072205P 2005-05-13 2005-05-13
PCT/US2006/017922 WO2006124413A2 (en) 2005-05-13 2006-05-10 Methods for treating drug resistant cancer

Publications (1)

Publication Number Publication Date
DK1885187T3 true DK1885187T3 (da) 2013-12-09

Family

ID=37431829

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06752445.4T DK1885187T3 (da) 2005-05-13 2006-05-10 Fremgangsmåde til behandling af lægemiddelresistent cancer

Country Status (23)

Country Link
US (1) US8299081B2 (da)
EP (1) EP1885187B1 (da)
JP (2) JP5344910B2 (da)
KR (1) KR101319122B1 (da)
CN (1) CN101222850B (da)
AU (1) AU2006247803B2 (da)
BR (1) BRPI0610360A2 (da)
CA (1) CA2608171C (da)
DK (1) DK1885187T3 (da)
ES (1) ES2440799T3 (da)
HK (1) HK1110477A1 (da)
IL (1) IL187327A (da)
MA (1) MA29543B1 (da)
MX (1) MX2007014206A (da)
NO (1) NO20076425L (da)
NZ (1) NZ564144A (da)
PL (1) PL1885187T3 (da)
PT (1) PT1885187E (da)
RU (1) RU2426539C2 (da)
SI (1) SI1885187T1 (da)
TN (1) TNSN07419A1 (da)
WO (1) WO2006124413A2 (da)
ZA (1) ZA200709620B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101423513B (zh) * 2007-10-29 2013-03-27 中国医学科学院药物研究所 胺基嘧啶衍生物、及其制法和药物组合物与用途
DK2149372T3 (da) 2008-07-31 2014-07-07 Universität Ulm Anvendelse af opioider af metadongruppen til behandling af patienter med resistent cancer
US9095592B2 (en) * 2008-11-07 2015-08-04 The Research Foundation For The State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US9519613B2 (en) * 2009-02-02 2016-12-13 Asurion, Llc Method for integrating applications in an electronic address book
US8492374B2 (en) 2009-04-29 2013-07-23 Industrial Technology Research Institute Azaazulene compounds
CA2795089A1 (en) * 2010-04-16 2011-10-20 Novartis Ag Combination of organic compounds
US20150182525A1 (en) * 2011-05-19 2015-07-02 Novartis Ag 4-Amino-5-Fluoro-3-[6-(4-Methylpiperazin-1-YL)-1H-Benzimidazol-2-YL]-1H-Quinolin-2-one for use in the Treatment of Adenoid Cystic Carcinoma
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
MX2014009303A (es) * 2012-01-31 2014-10-14 Novartis Ag Combinacion de un inhibidor de rtk con un anti-estrogeno y uso del mismo para el tratamiento de cancer.
CA2878251A1 (en) 2012-07-11 2014-01-16 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
RU2547999C1 (ru) * 2013-10-28 2015-04-10 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения аденогенного местно-распространенного рака нижнеампулярного отдела прямой кишки
WO2016123054A2 (en) * 2015-01-26 2016-08-04 The University Of North Carolina At Chapel Hill Kinase drug combinations and methods of use thereof
EP3515559A4 (en) * 2016-09-20 2020-07-15 Dana-Farber Cancer Institute, Inc. COMPOSITIONS AND METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION AND TREATMENT OF AML USING USP10 BIOMARKERS AND MODULATORS

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US580883A (en) * 1897-04-20 Logging-sled
US3663606A (en) 1966-06-21 1972-05-16 Mitsui Toatsu Chemicals Organic imino-compounds
DE2363459A1 (de) 1973-12-20 1975-06-26 Basf Ag Neue fluoreszierende chinolinverbindungen
DE3248043A1 (de) 1982-12-24 1984-06-28 Bayer Ag, 5090 Leverkusen Fluorogene phosphorsaeureester, verfahren zu deren herstellung sowie verfahren und mittel zum nachweis und zur fluorometrischen bestimmung von phosphaten
US4659657A (en) 1982-12-24 1987-04-21 Bayer Aktiengesellschaft Chromogenic and fluorogenic esters for photometric or fluorimetric determination of phosphatases or sulphatases
DE3634066A1 (de) 1986-10-07 1988-04-21 Boehringer Mannheim Gmbh Neue 5-alkylbenzimidazole, verfahren zu ihrer herstellung sowie arzneimittel
US5073492A (en) 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
JPH07121937B2 (ja) 1987-03-18 1995-12-25 大塚製薬株式会社 カルボスチリル誘導体
JPH0699497B2 (ja) 1987-04-16 1994-12-07 富士写真フイルム株式会社 光重合性組成物
GB8709448D0 (en) 1987-04-21 1987-05-28 Pfizer Ltd Heterobicyclic quinoline derivatives
JPH02229165A (ja) 1989-03-02 1990-09-11 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
DE3932953A1 (de) 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5151360A (en) 1990-12-31 1992-09-29 Biomembrane Institute Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
GB9107742D0 (en) 1991-04-11 1991-05-29 Rhone Poulenc Agriculture New compositions of matter
GB9108369D0 (en) 1991-04-18 1991-06-05 Rhone Poulenc Agriculture Compositions of matter
GB9108547D0 (en) 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ES2108120T3 (es) 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
USRE37650E1 (en) 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5856115A (en) 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
CA2452130A1 (en) 1992-03-05 1993-09-16 Francis J. Burrows Methods and compositions for targeting the vasculature of solid tumors
JP3142378B2 (ja) 1992-06-22 2001-03-07 ティーディーケイ株式会社 有機ｅｌ素子
AU673193B2 (en) 1992-09-02 1996-10-31 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
US5763441A (en) 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5792771A (en) 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5981569A (en) 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
JPH0743896A (ja) 1993-07-28 1995-02-14 Toyobo Co Ltd 光重合性組成物
US5498608A (en) 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
AU5881394A (en) 1994-01-08 1995-08-01 Rhone-Poulenc Agriculture Limited Benzimidazolyl quinoline-3-carboxylate derivatives, intermediates thereto, and their use as herbicides
JPH0829973A (ja) 1994-07-11 1996-02-02 Toyobo Co Ltd 光重合性組成物
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
JP3441246B2 (ja) 1995-06-07 2003-08-25 富士写真フイルム株式会社 光重合性組成物
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
CA2238975A1 (en) 1995-12-12 1997-06-19 Merck & Co., Inc. New use for losartan
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6010711A (en) 1996-01-26 2000-01-04 University Of Rochester Methods, articles and compositions for the pharmacologic inhibition of bone resorption with phosphodiesterase inhibitors
DE19610723A1 (de) 1996-03-19 1997-09-25 Bayer Ag Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen
US5942385A (en) 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
US6111110A (en) 1996-10-30 2000-08-29 Eli Lilly And Company Synthesis of benzo[f]quinolinones
US6245760B1 (en) 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
DE19756235A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
WO1999059636A1 (fr) 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Inhibiteurs de l'activite du facteur de croissance endothelial vasculaire (vegf)
US6174912B1 (en) 1998-08-21 2001-01-16 Dupont Pharmaceuticals Company Nitrogen substituted imidazo[4,5-C]pyrazoles as corticotropin releasing hormone antagonists
DE19841985A1 (de) 1998-09-03 2000-03-09 Schering Ag Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate
US20030087854A1 (en) 2001-09-10 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of fibroblast growth factor receptor 3 expression
JP4707240B2 (ja) 1999-05-05 2011-06-22 アベンティス・フアーマ・リミテッド 細胞接着調節剤としての尿素
KR100298572B1 (ko) 1999-08-19 2001-09-22 박찬구 카바아닐라이드로부터 4-니트로디페닐아민과 4-니트로소디페닐아민의 제조방법
ATE290865T1 (de) 1999-10-19 2005-04-15 Merck & Co Inc Tyrosin kinase inhibitoren
AU778588B2 (en) 1999-10-19 2004-12-09 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
CN100488517C (zh) 2000-03-07 2009-05-20 拉什-长老会-圣路加医学中心 捕获和灭活病原性微生物和精子的组合物及其制药用途
EP1314425A4 (en) 2000-08-30 2004-06-02 Sankyo Co MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
US7179912B2 (en) 2000-09-01 2007-02-20 Icos Corporation Materials and methods to potentiate cancer treatment
AU2001293233A1 (en) 2000-09-01 2002-03-13 Chiron Corporation Aza heterocyclic derivatives and their therapeutic use
JP4361727B2 (ja) 2000-09-11 2009-11-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド チロシンキナーゼインヒビターとしてのキノリノン誘導体
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
EP1401831A1 (en) 2001-07-03 2004-03-31 Chiron Corporation Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
US20030159702A1 (en) 2002-01-21 2003-08-28 Lindell Katarina E.A. Formulation and use manufacture thereof
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
JP4613130B2 (ja) 2002-08-23 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ベンゾイミダゾールキノリノンおよびそれらの使用
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
CA2501932C (en) 2002-11-13 2014-03-11 Chiron Corporation Use of benzimidazole quinolinones for treating cancer
US6774327B1 (en) 2003-09-24 2004-08-10 Agilent Technologies, Inc. Hermetic seals for electronic components
MXPA06004199A (es) 2003-10-17 2006-06-28 Novo Nordisk As Terapia en combinacion.
CN102225926A (zh) * 2003-11-07 2011-10-26 诺华疫苗和诊断公司 具有改进药物特性的喹啉酮类化合物的药学上可接受的盐
CA2556872C (en) 2004-02-20 2015-05-12 Chiron Corporation Modulation of inflammatory and metastatic processes
AU2006208012B2 (en) * 2005-01-27 2011-08-04 Novartis Vaccines And Diagnostics Inc. Treatment of metastasized tumors
EP1885801A1 (en) 2005-05-18 2008-02-13 M & G Polimeri Italia S.P.A. Polyester composition
JP2009543810A (ja) 2006-07-13 2009-12-10 ザイモジェネティクス， インコーポレイテッド インターロイキン２１およびチロシンキナーゼ阻害剤の併用治療の方法
EP2049904A1 (en) 2006-07-28 2009-04-22 Novartis Ag Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma

Also Published As

Publication number Publication date
WO2006124413A2 (en) 2006-11-23
PL1885187T3 (pl) 2014-03-31
CA2608171C (en) 2014-02-04
AU2006247803A1 (en) 2006-11-23
ES2440799T3 (es) 2014-01-30
JP2013173787A (ja) 2013-09-05
CA2608171A1 (en) 2006-11-23
MX2007014206A (es) 2008-02-07
NO20076425L (no) 2008-01-30
RU2426539C2 (ru) 2011-08-20
KR101319122B1 (ko) 2013-10-23
IL187327A0 (en) 2008-04-13
CN101222850A (zh) 2008-07-16
CN101222850B (zh) 2012-10-03
KR20080033902A (ko) 2008-04-17
HK1110477A1 (en) 2008-07-18
PT1885187E (pt) 2013-12-16
IL187327A (en) 2015-05-31
US8299081B2 (en) 2012-10-30
TNSN07419A1 (en) 2009-03-17
EP1885187A4 (en) 2009-05-13
NZ564144A (en) 2009-11-27
MA29543B1 (fr) 2008-06-02
SI1885187T1 (sl) 2013-12-31
EP1885187B1 (en) 2013-09-25
BRPI0610360A2 (pt) 2010-06-15
JP5344910B2 (ja) 2013-11-20
ZA200709620B (en) 2008-10-29
JP2008540543A (ja) 2008-11-20
EP1885187A2 (en) 2008-02-13
RU2007145932A (ru) 2009-06-20
AU2006247803B2 (en) 2011-12-22
US20090215793A1 (en) 2009-08-27
WO2006124413A3 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
DK1885187T3 (da) Fremgangsmåde til behandling af lægemiddelresistent cancer
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
EA200702363A1 (ru) Новые лиганды гистамина h-рецептора и их терапевтические применения
HK1131608A1 (en) Pyridinone compounds
MX2009008439A (es) Nuevos inhibidores de la replicacion del virus de hepatitis c.
EA201100030A1 (ru) Пиразольные соединения 436
EA201170772A1 (ru) Органические соединения
EA200700501A1 (ru) Композиция (варианты) и способ для лечения гиперпролиферативных процессов, способ лечения рака (варианты) и способ получения твёрдой дисперсии вещества
BRPI0915084B8 (pt) composto, e, composição farmacêutica
EA201490396A1 (ru) Ингибиторы репликации вирусов гриппа
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
EA201270570A1 (ru) Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90
EA201100136A1 (ru) 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
EA201001772A1 (ru) Производные 3,5-диамино-6-хлорпиразин-2-карбоновой кислоты и их применение в качестве блокаторов эпителиальных натриевых каналов для лечения заболеваний дыхательных путей
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
EA200800302A1 (ru) Применение производных и аналогов тиазола при лечении рака
EA200700601A1 (ru) Производные фениламинопиримидина как ингибиторы bcr-abl
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
EA201370191A1 (ru) КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ